The anaemia treatment journey of CKD patients: from epoetins to hypoxia-inducible factor-prolyl hydroxylase inhibitors

The discovery and development of erythropoiesis-stimulating agents was a journey lasting more than a century, leading to the cloning and approval of recombinant human erythropoietin (rHuEpo). This was an impressive clinical advance, providing the possibility of correcting the symptoms associated wit...

Descripción completa

Detalles Bibliográficos
Autores principales: Locatelli, Francesco, Del Vecchio, Lucia, Elliott, Steve
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
CKJ Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10539216/
https://www.ncbi.nlm.nih.gov/pubmed/37779852
http://dx.doi.org/10.1093/ckj/sfad105

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10539216/
https://www.ncbi.nlm.nih.gov/pubmed/37779852
http://dx.doi.org/10.1093/ckj/sfad105

Ejemplares similares